CJC-1295 + Ipamorelin Blend (5mg + 5mg)
10mg blendA widely studied growth hormone secretagogue blend combining a long-acting GHRH analogue with a selective ghrelin-receptor agonist for reference research into GH pulse dynamics.
Overview
CJC-1295 and Ipamorelin are frequently paired in preclinical research because they act on two complementary pathways of growth hormone (GH) release. CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue that mimics ghrelin at the GHS-R1a receptor.
This 10mg blend (5mg CJC-1295 with 5mg Ipamorelin) is supplied as a lyophilised powder for laboratory reconstitution. It is one of the most commonly referenced combinations in published secretagogue literature due to the additive effect the two peptides show on GH output in model systems.
Mechanism of action
CJC-1295 binds the GHRH receptor on the anterior pituitary, promoting the synthesis and release of growth hormone. Modified variants extend its half-life, allowing a sustained elevation of GH and IGF-1 baseline in research models.
Ipamorelin acts on a separate receptor (GHS-R1a) and stimulates a GH pulse without the appetite, cortisol, or prolactin elevation associated with earlier secretagogues. When studied together, the GHRH analogue raises the amplitude of the pulse that Ipamorelin triggers, producing a larger combined GH response than either compound alone.
Research highlights
Studies of GHRH analogues report sustained increases in circulating GH and IGF-1 in animal and in-vitro models, supporting research into somatotropic axis regulation.
Ipamorelin has been characterised in the literature as one of the most selective GH secretagogues, showing minimal off-target hormone release, which makes the blend useful for isolating GH-specific effects in study designs.
Reference dosing
CJC-1295 + Ipamorelin stacks are described in research protocols as being dosed nightly or 1-3x/day away from food to align with natural GH pulses. Reference cycles in the literature commonly run 8-12 weeks. This information reflects published research protocols only.
Storage & handling
Store lyophilised vials refrigerated at 2-8C and protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within the period indicated by your protocol.
Specifications
| Contents | CJC-1295 5mg + Ipamorelin 5mg |
| Form | Lyophilised powder |
| Presentation | Single vial (10mg blend) |
| Purity | >=99% (HPLC) |
| Reconstitution | Bacteriostatic water (not included) |
Frequently asked questions
What is the CJC-1295 and Ipamorelin blend used for?
It is a research-only growth hormone secretagogue blend used in laboratory studies of GH and IGF-1 signalling. It is not for human use.
Why are CJC-1295 and Ipamorelin combined?
They act on two different receptors (GHRH and GHS-R1a). Research shows the two pathways produce an additive growth hormone response when studied together.
How is the blend supplied?
As a single lyophilised powder vial containing 5mg CJC-1295 and 5mg Ipamorelin, requiring reconstitution with bacteriostatic water for research.